Protein and Energy Metabolism in Pediatric Crohn's Disease
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The metabolic response to Crohn's disease, including increased proteolysis and lipolysis and
changes in energy expenditure, plays a significant role in the resulting malnutrition from
which these patients suffer. Tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory
cytokine, has been found to be elevated in children with ulcerative colitis. TNF-alpha has
been incriminated in the mechanism of weight loss in many different chronic diseases, and
causes net protein and lipid catabolism. Anti-TNF-alpha antibody (infliximab) has been proven
to be an effective therapy for ulcerative colitis.
The purpose of this study is to compare changes in protein and lipid metabolism, as well as
resting energy expenditure, before and after therapy with anti-TNF-alpha antibody
(infliximab) or corticosteroids in children with recurrent Crohn's disease. Performing this
study will better define the changes in nutrition status observed in these children following
remission of active Crohn's disease, and potentially lead to changes in medical and
nutritional management of these children.
Phase:
Phase 1
Details
Lead Sponsor:
Indiana University
Collaborators:
Crohn's and Colitis Foundation GlaxoSmithKline National Center for Research Resources (NCRR)